Please assess the completion status of the following clinical trial:

Trial Title: Randomized Trial of Gemcitabine/Cisplatin Versus S-1/Cisplatin in Advanced Biliary Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age : older than 20~* Eastern Cooperative Oncology Group (ECOG) performance status 0 -2~* Histologically confirmed adenocarcinoma of the biliary tract~* Metastatic or unresectable biliary cancer~* No prior chemotherapy for biliary cancer~* A patient with at least one measurable primary lesion of which the diameter is confirmed to be 10mm in Spiral CT or multidetector CT (MD CT)~* Adequate bone marrow, liver, renal function~Exclusion Criteria:~* A patient with no measurable disease~* A patient who received previous palliative chemotherapy for biliary cancer~* A patient who received adjuvant chemotherapy for biliary cancer within 1year~* A patient with previous active or passive immunotherapy.~* A pregnant or lactating patient

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Gemcitabine/Cisplatin (Type: EXPERIMENTAL): None
- S-1/Cisplatin (Type: EXPERIMENTAL): D1-14 S-1 40mg/m2 po bid D1,D8 Cisplatin 25/m2 + N/S 150cc miv over 60mins Repeated every 3 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).